This study is in progress, not accepting new patients
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Chronic Lymphocytic Leukemia, CLL, Ibrutinib, Obinutuzumab, Cancer, Leukemia, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell, GA101+ibrutinib
Lead Scientist at UCSD
- Thomas J. Kipps, MD, PhD
Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.
- in progress, not accepting new patients
- Start Date
- Completion Date
- University of California, San Diego
- Phase 1/2 research study
- Study Type
- Expecting 32 study participants
- Last Updated